^
    3d
    OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 --> Jun 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    3d
    TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, First Hospital of China Medical University
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • Trodelvy (sacituzumab govitecan-hziy)
    3d
    Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study. (PubMed, Breast Cancer Res Treat)
    This first international real-world series of SG in mMpTNBC shows clinically relevant activity and manageable toxicity, addressing a critical evidence gap and supporting further prospective studies, particularly in PD-L1-positive disease.
    Retrospective data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Trodelvy (sacituzumab govitecan-hziy)
    7d
    Interrogating the Involvement of Autophagy, Senescence, and the Immune System in the Actions of Sacituzumab Govitecan as an Anticancer Agent. (PubMed, Front Biosci (Landmark Ed))
    While SG has shown significant clinical benefit, the objective response rate (ORR) observed with SG in pretreated mTNBC patients in the Phase I/II basket study was 33.3%, indicating a heterogeneous response profile to SG. This article explores the potential influence of autophagy, senescence, and the patient's immune system on the treatment response.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    7d
    WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=76, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
    7d
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)
    8d
    Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED (clinicaltrials.gov)
    P2, N=50, Completed, MedSIR | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim) • loperamide
    8d
    CA209-63Y: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients (clinicaltrials.gov)
    P1/2, N=46, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Apr 2026 --> Sep 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Trodelvy (sacituzumab govitecan-hziy)
    9d
    TROPION Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=744, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Jun 2026 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk)
    10d
    A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (clinicaltrials.gov)
    P3, N=1023, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Jiataile (sacituzumab tirumotecan)
    10d
    Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Sep 2026 --> Jul 2027
    Trial completion date • Platinum sensitive
    |
    cisplatin • Trodelvy (sacituzumab govitecan-hziy)
    11d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)